Akums Drugs & Pharmaceuticals Ltd
Akums Drugs & Pharmaceuticals Q4 FY26 earnings call: Revenue & Margins
Q4 FY26 earnings call: what management guided on revenue, margins and order book.
The short version
CDMO segment expects double-digit volume growth in H1 FY27; overall revenue growth guidance not specifically stated yet. CDMO business expects double-digit volume growth in H1 FY27 with similar margin profile as current (around 13-14%) and potential improvement due to new European and Zambia contracts leading to better margins (potentially 15-16%).
From Akums Drugs & Pharmaceuticals Ltd's Q4 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- CDMO segment expects double-digit volume growth in H1 FY27; overall revenue growth guidance not specifically stated yet.
- European CDMO contract projected to contribute around EUR35 million annually from FY28, adding to revenue.
- Anticipated improvement in CDMO margins to mid-teens (15-16%) as international contracts scale up.
- Domestic formulations expected to grow in line with Indian Pharmaceutical Market (IPM) with double-digit top-line growth driven by volume, price, and NII growth.
- Trade generics expected to reduce EBITDA losses sizably with a goal to achieve monthly positive EBITDA within a few quarters.
- Oral solid facility expansion underway to support volume growth.
2 more points management made on revenue & sales performance
Profitability & Margins
See what Akums Drugs & Pharmaceuticals Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Current capex for FY26 was INR 222 crores; targeted capex for FY27 is INR 300 crores.
- Ongoing expansion of the oral solid facility to support over 20% volume growth.
- Investment in ramping up new injectable, Penem, and Baddi plants progressing with client audits and product approvals underway.
- No plans for new facilities or new dosage forms specifically for international CDMO; focus is on utilizing existing advanced injectable and hormone facilities.
- Evaluating inorganic opportunities in branded portfolios, though current market valuations are high.
- SAP S/4HANA digital transformation and Darwinbox HR implementation underway for operational efficiency.
2 more points management made on capital expenditure plans
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Akums Drugs & Pharmaceuticals Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- The company is actively engaged with 8 to 10 global CDMO customers expected over the next 2-3 years.
- For FY28, export CDMO revenues are projected around EUR70 million (approximately INR680 crores).
- The European contract alone is expected to deliver about EUR35 million on a MAT basis annually starting FY28.
- The Zambia contract will contribute approximately $25 million annually in FY27 and FY28.
- These long-term contracts have a ramp-up period of 2-3 years due to dossier clearances and regulatory approvals.
2 more points management made on order book & pipeline
Akums Drugs & Pharmaceuticals Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹1.2K Cr, net profit ₹81 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Akums Drugs's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Aptus Pharma Ltd (Q4 FY26)
The investor presentation reports quarterly revenue of ₹40.36 crore for Q4 FY2026. Key concall takeaways from Aptus Pharma Ltd's Q4 FY26 earnings call — and…
- Morepen Laboratories Ltd (Q4 FY26)
472 crore, up 22% year-on-year (YoY) from Rs. Key concall takeaways from Morepen Laboratories Ltd's Q4 FY26 earnings call — and how it ranks against sector…
- Anuh Pharma Ltd (Q4 FY26)
202.12 Cr., a 2.50% increase quarter-on-quarter (Page 14) . Key concall takeaways from Anuh Pharma Ltd's Q4 FY26 earnings call — and how it ranks against…
- Themis Medicare Ltd (Q4 FY26)
Q4 FY26 Net Revenue: ₹76.53 crore, up 6.7% YoY from ₹71.70 crore in Q4 FY25 (Page 8). Key concall takeaways from Themis Medicare Ltd's Q4 FY26 earnings call…
Frequently Asked Questions
What were Akums Drugs & Pharmaceuticals Ltd Q4 FY26 results?
CDMO segment expects double-digit volume growth in H1 FY27; overall revenue growth guidance not specifically stated yet. CDMO business expects double-digit volume growth in H1 FY27 with similar margin profile as current (around 13-14%) and potential improvement due to new European and Zambia contracts leading to better margins (potentially 15-16%).
What is Akums Drugs & Pharmaceuticals Ltd share price analysis?
Akums Drugs & Pharmaceuticals Ltd currently shows a neutral. The stock trades at a P/E of 37.5 with a market cap of ₹11,436 Cr. Investors should review the full earnings analysis for detailed insights.
Is Akums Drugs & Pharmaceuticals Ltd planning capital expenditure?
Current capex for FY26 was INR 222 crores; targeted capex for FY27 is INR 300 crores.
Keep Akums Drugs & Pharmaceuticals Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.